Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

J. Marková, P. Michková, K. Burčková, J. Březinová, K. Michalová, A. Dohnalová, JS. Maaloufová, P. Soukup, A. Vítek, P. Cetkovský, J. Schwarz

. 2012 ; 88 (2) : 128-135.

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12022263

OBJECTIVES: Recently, mutations in DNMT3A gene have been described in about 25% acute myeloid leukemia (AML) cases, preferentially in monocytic AML. They were found to predict worse overall survival (OS) of mutated patients. PATIENTS AND METHODS: RT-PCR followed by direct sequencing was used to test the presence of DNMT3A mutations in 226 AML patients with an intermediate-risk (IR) cytogenetics. RESULTS: Sixty-seven patients of 226 (29.6%) carried a mutation in the DNMT3A gene. Occurrence of DNMT3A mutations was associated with female sex (P = 0.027) and with the presence of FLT3/ITD (P = 0.003), but not with particular FAB subtypes. Patients with DNMT3A mutation had higher initial WBC counts than those without it (P = 0.064) only because of higher incidence of FLT3/ITD within these cases. There was no difference between mutated and wild-type groups in reaching complete remission (CR) (P = 0.380). OS was not affected by DNMT3A mutation (P = 0.251), but OS of patients who reached CR was longer in DNMT3A negative cases (P = 0.025). Patients with DNMT3A mutation had a higher relapse rate (P = 0.007). Patients carrying both the DNMT3A mutation and FLT3/ITD relapsed more often than either patients with single DNMT3A mutation (P = 0.044) or patients with FLT3/ITD only (P = 0.058). DNMT3A mutations were associated with higher relapse rate even within the FLT3/ITD-negative group (P = 0.072). After reaching CR, these two genetic factors were independent predictors of relapse at multivariate analysis (P < 0.001). Only three of 30 'double-mutated' (FLT3/ITD+, DNMT3A+) patients are still alive, all of them having undergone hematopoietic stem cell transplant. CONCLUSIONS: We have confirmed the high incidence of DNMT3A mutations in patients with AML with IR cytogenetics. Patients with DNMT3A mutations relapse more often and have inferior OS when only patients achieving CR are analyzed. 'Double-mutated' patients have a very poor prognosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022263
003      
CZ-PrNML
005      
20160323104136.0
007      
ta
008      
120806s2012 xxk f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1600-0609.2011.01716.x $2 doi
035    __
$a (PubMed)21967546
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Marková, Jana $7 xx0139684 $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
245    10
$a Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia / $c J. Marková, P. Michková, K. Burčková, J. Březinová, K. Michalová, A. Dohnalová, JS. Maaloufová, P. Soukup, A. Vítek, P. Cetkovský, J. Schwarz
520    9_
$a OBJECTIVES: Recently, mutations in DNMT3A gene have been described in about 25% acute myeloid leukemia (AML) cases, preferentially in monocytic AML. They were found to predict worse overall survival (OS) of mutated patients. PATIENTS AND METHODS: RT-PCR followed by direct sequencing was used to test the presence of DNMT3A mutations in 226 AML patients with an intermediate-risk (IR) cytogenetics. RESULTS: Sixty-seven patients of 226 (29.6%) carried a mutation in the DNMT3A gene. Occurrence of DNMT3A mutations was associated with female sex (P = 0.027) and with the presence of FLT3/ITD (P = 0.003), but not with particular FAB subtypes. Patients with DNMT3A mutation had higher initial WBC counts than those without it (P = 0.064) only because of higher incidence of FLT3/ITD within these cases. There was no difference between mutated and wild-type groups in reaching complete remission (CR) (P = 0.380). OS was not affected by DNMT3A mutation (P = 0.251), but OS of patients who reached CR was longer in DNMT3A negative cases (P = 0.025). Patients with DNMT3A mutation had a higher relapse rate (P = 0.007). Patients carrying both the DNMT3A mutation and FLT3/ITD relapsed more often than either patients with single DNMT3A mutation (P = 0.044) or patients with FLT3/ITD only (P = 0.058). DNMT3A mutations were associated with higher relapse rate even within the FLT3/ITD-negative group (P = 0.072). After reaching CR, these two genetic factors were independent predictors of relapse at multivariate analysis (P < 0.001). Only three of 30 'double-mutated' (FLT3/ITD+, DNMT3A+) patients are still alive, all of them having undergone hematopoietic stem cell transplant. CONCLUSIONS: We have confirmed the high incidence of DNMT3A mutations in patients with AML with IR cytogenetics. Patients with DNMT3A mutations relapse more often and have inferior OS when only patients achieving CR are analyzed. 'Double-mutated' patients have a very poor prognosis.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a chromozomální aberace $7 D002869
650    _2
$a kodon $7 D003062
650    _2
$a DNA-(cytosin-5-)methyltransferasa $x genetika $7 D004248
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a akutní myeloidní leukemie $x genetika $x mortalita $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
650    _2
$a indukce remise $7 D012074
650    _2
$a rizikové faktory $7 D012307
650    _2
$a mladý dospělý $7 D055815
650    _2
$a tyrosinkinasa 3 podobná fms $x metabolismus $7 D051941
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Michková, Petra $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Burčková, Kateřina $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Březinová, Jana, $d 1958- $7 xx0046958 $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Michalová, Kyra, $d 1942- $7 nlk19990073558 $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Dohnalová, Alena $7 xx0062948 $u Institute of Physiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Maaloufová, Jacqueline $7 xx0064317 $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Soukup, Petr $7 xx0250579 $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Vítek, Antonín $7 xx0061805 $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Cetkovský, Petr, $d 1959- $7 xx0025652 $u Institute of Hematology and Blood Transfusion, Prague
700    1_
$a Schwarz, Jiří, $d 1957- $7 xx0052837 $u Institute of Hematology and Blood Transfusion, Prague
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 88, č. 2 (2012), s. 128-135
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21967546 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20160323104203 $b ABA008
999    __
$a ok $b bmc $g 944176 $s 779560
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 88 $c 2 $d 128-135 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$b NLK111 $a Pubmed-20120806/12/01

Find record

Citation metrics

Archiving options